Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Change in Cash: 2017-2025

Historic Change in Cash for Denali Therapeutics (DNLI) over the last 9 years, with Sep 2025 value amounting to -$50.2 million.

  • Denali Therapeutics' Change in Cash fell 414.87% to -$50.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 103.24%. This contributed to the annual value of $47.9 million for FY2024, which is 152.67% up from last year.
  • Denali Therapeutics' Change in Cash amounted to -$50.2 million in Q3 2025, which was down 159.63% from $84.3 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Change in Cash registered a high of $99.4 million during Q4 2022, and its lowest value of -$188.5 million during Q1 2022.
  • Its 3-year average for Change in Cash is -$11.4 million, with a median of $14.1 million in 2024.
  • Per our database at Business Quant, Denali Therapeutics' Change in Cash surged by 503.37% in 2024 and then tumbled by 414.87% in 2025.
  • Denali Therapeutics' Change in Cash (Quarterly) stood at -$101.1 million in 2021, then spiked by 198.37% to $99.4 million in 2022, then crashed by 121.03% to -$20.9 million in 2023, then soared by 503.37% to $84.3 million in 2024, then tumbled by 414.87% to -$50.2 million in 2025.
  • Its Change in Cash was -$50.2 million in Q3 2025, compared to $84.3 million in Q2 2025 and -$116.5 million in Q1 2025.